Literature DB >> 22320398

Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.

Atsushi Shimizu1, Seiko Hirono, Masaji Tani, Manabu Kawai, Ken-Ichi Okada, Motoki Miyazawa, Yuji Kitahata, Yasushi Nakamura, Tetsuo Noda, Shozo Yokoyama, Hiroki Yamaue.   

Abstract

The invasion process is a crucial step for pancreatic ductal adenocarcinoma (PDAC); however, the genes related to invasion remain unclear. To identify specific genes for the invasion process, we compared microarray data for infiltrating cancer and PanIN-3, which were harvested from an individual PDAC patient by microdissection. Furthermore, immunohistochemical, coimmunoprecipitation and invasion analyses were performed to confirm the biologic significance of molecules identified by expression profile. In the present study, we focused on MUC16 and mesothelin among 87 genes that were significantly upregulated in infiltrating components compared to PanIN-3 in all PDAC patients, because MUC16 was the most differently expressed between two regions, and mesothelin was reported as the receptor for MUC16. Immunohistochemical analysis revealed that MUC16 and mesothelin were expressed simultaneously only in infiltrating components and increased at the invasion front, and binding of MUC16 and mesothelin was found in PDAC by immunoprecipitation assay. The downregulation of MUC16 by shRNA and the blockage of MUC16 binding to mesothelin by antibody inhibited both invasion and migration of pancreatic cancer cell line. MUC16 high/mesothelin high expression was an independent prognostic factor for poor survival in PDAC patients. In conclusion, we identified two specific genes, MUC16 and mesothelin, associated with the invasion process in patients with PDAC.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320398     DOI: 10.1111/j.1349-7006.2012.02214.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  51 in total

1.  [Unilateral swelling of the lacrimal gland in a 15-year-old female patient].

Authors:  A I Berta; N Naumann-Bartsch; A Agaimy; M Metzler; F E Kruse; L Holbach
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 3.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 4.  CAR T-cell therapy for pancreatic cancer.

Authors:  Carl J DeSelm; Zachary E Tano; Anna M Varghese; Prasad S Adusumilli
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 3.454

Review 5.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

6.  Engineered Fn3 protein has targeted therapeutic effect on mesothelin-expressing cancer cells and increases tumor cell sensitivity to chemotherapy.

Authors:  Allison R Sirois; Daniela A Deny; Yanxuan Li; Yacine D Fall; Sarah J Moore
Journal:  Biotechnol Bioeng       Date:  2019-11-12       Impact factor: 4.530

Review 7.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

Review 8.  Clinical impacts of mesothelin expression in gastrointestinal carcinomas.

Authors:  Takahiro Einama; Futoshi Kawamata; Hirofumi Kamachi; Hiroshi Nishihara; Shigenori Homma; Fumihiko Matsuzawa; Tatsuzo Mizukami; Yuji Konishi; Munenori Tahara; Toshiya Kamiyama; Okio Hino; Akinobu Taketomi; Satoru Todo
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15

Review 9.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

10.  Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.

Authors:  Yukinori Koyama; Ping Wang; Shuang Liang; Keiko Iwaisako; Xiao Liu; Jun Xu; Mingjun Zhang; Mengxi Sun; Min Cong; Daniel Karin; Kojiro Taura; Chris Benner; Sven Heinz; Tapan Bera; David A Brenner; Tatiana Kisseleva
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.